1Dargaville PA, Copnell B. Australian and New Zealand Neonatal Network. The epidemiology of meconium aspiration syndrome: incidence, risk factors, therapies, and outcome. Pediatrics, 2006,117 : 1712-1721.
2Qian L, Liu C, Zhuang W, et al. Neonatal respiratory failure: a 12-month clinical epidemiologic study from 2004 to 2005 in China. Pediatrics, 2008,121 : e1115-1124.
3Vain NE, Szyld EG, Prudent LM, et 81. Oropharyngeal and nasopharyngeal suctioning of meconium-stained neonates before delivers' of their shoulders: muhicentre, randomised controlled trial. Lancet, 2004,364:597-602.
4American Heart Association ; American Academy of Pediatrics. 2005 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: neonatal resuscitation guidelines. Pediatrics, 2006,117 :e1029-1038.
6Lotze A, Mitchell BR, Bulas DI, et al. Muhicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr, 1998,132:40-47.
7Soll RF, Dargaville P. Surfactant for meconium aspiration syndrome in full term infants. Cochrane Database Syst Rev, 2000: CD002054.
8Chinese Collaborative Study Group for Neonatal Respiratory Diseases. Treatment of severe meconium aspiration syndrome with porcine surfactant: a muhicentre, randomized, controlled trial. Acta Paediatr, 2005,94:896-902.
9Wiswell TE, Knight GR, Finer NN, et al. A muhicenter, randomized, controlled trial comparing Suffaxin (Lucinactant) layage with standard care for treatment of meconium aspiration syndrome. Pediatrics, 2002,109 : 1081-1087.
10Nakamura T, Matsuzawa S, Sugiura M, et al. A randomised control study of partial liquid ventilation after airway lavage with exogenous surfactant in a meconium aspiration syndrome animal model. Arch Dis Child Fetal Neonatal Ed, 2000,82 : F160-162.
2Kang JL, Park W, Pack IS, et aL Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. J Appl Physiol, 2002, 92 : 795-801.
3Hu X, Cao L, Lain LK, et al. Mitigation of meconium-induced lung injury by surfactant and inhaled nitric oxide is associated with suppression of nuclear transcription factor kappa B. Biol Neonate, 2005, 87:73-81.
4Cao L, Qian LI, Zhu YR, et al. Regulation of activity of nuclear factor-kappa B and activator protein-I by nitric oxide, surfactant and glucocorticoids in alveolar macrophages from piglets with acute lung injury. Acta Pharmacol Sin, 2003, 24: 1316-1323.
5Chollet-Martin S, Jourdain B, Gibert C, et al. Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Am J Respir Crit Care Med, 1996, 154: 594-601.
6Jean D, Maitre B, Tankovic J, et al. Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance. Crit Cave Med, 2002, 30: 442-447.
7Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with repiratory failure. N Engl J Med, 2006, 355:354-364.
8Cleary G, Wiswen TE. Meconium-stained amniotic fluid and the meconium aspiration syndrome: an update. Pediatr Clin Noah Am, 1998, 45:511-529.
9Femandez-Martorell P, Rais-Bahrami K, Rivera O, et aL Use of nitric oxide in meconium aspiration syndrome: lack of response.Scand J Clin Lab Invest, 1998, 58:177-181.
10Kinsella JP, Truog WE, Walsh WF, et aL Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr, 1997, 131:55-62.
